Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25466890 | 1.00 | MEN1 (0.50) | MEN1KMT2AKDM4EPOLBTDP1 | |
| SCHEMBL22014884 | 1.00 | MEN1 (0.50) | MEN1KMT2AKDM4EPOLBTDP1 | |
| SCHEMBL18908647 | 1.00 | MEN1 (0.50) | MEN1KMT2AKDM4EPOLBTDP1 | |
| SCHEMBL23806133 | 1.00 | MEN1 (0.50) | MEN1KMT2AKDM4EPOLBTDP1 | |
| SCHEMBL18738984 | 0.98 | MEN1 (0.47) | MEN1KMT2AKDM4EPOLBTDP1 | |
| SCHEMBL18973009 | 0.92 | MEN1 (0.46) | MEN1KMT2AKDM4EPOLBTDP1 | |
| SCHEMBL25851515 | 0.90 | MEN1 (0.47) | MEN1KMT2AKDM4ECYP1A2CYP2D6 | |
| SCHEMBL25885013 | 0.90 | MEN1 (0.52) | MEN1KMT2AKDM4EPOLBTDP1 | |
| SCHEMBL23190300 | 0.87 | MEN1 (0.58) | MEN1KMT2ARECQLSMN1; SMN2 | |
| SCHEMBL12572605 | 0.87 | MEN1 (0.58) | MEN1KMT2ARECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885KDM4E 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.